Candida isolates causing refractory or recurrent oropharyngeal candidiasis in 11 hospitals in China

Introduction: We studied the species distribution and antifungal susceptibilities of Candida isolates causing refractory or recurrent oropharyngeal candidiasis (OPC) in a multicenter study in China (2013–2016). Methods: Species identification was performed using the Bruker Biotyper (Bruker Daltonics, Germany) matrix-assisted laser desorption/ionization time of flight mass spectrometry system supplemented by internal transcribed spacer sequencing as required. Antifungal susceptibilities were determined by the Clinical and Laboratory Standards Institute document (CLSI) M27-A3 broth microdilution methodology. Results: A total of 558 non-duplicate Candida isolates comprising 10 species were obtained from 535 patients. Candida albicans was the most common species (89.6%), followed by C. glabrata (5.2%), C. tropicalis (2.9%), and C. parapsilosis (0.7%). Azoles were active against C. albicans with susceptibility rates of 96% and 95.8% for fluconazole and voriconazole, respectively. MIC50 values of C. albicans to fluconazole, voriconazole, itraconazole, and miconazole were 1, 0.03, 0.25 and 0.12 μg/mL, respectively, higher than those in previous studies of which OPC patients (corresponding MIC50 values of 0.25 , 0.015 , 0.06 , and 0.03 μg/mL). Except for itraconazole, the MIC50 and MIC90 values of 58 non-C. albicans to other azoles were two to threefold higher than C. albicans. Miconazole, amphotericin B, nystatin, and 5-flucytosine had good in vitro antifungal activity for all isolates. Conclusion: The study provides valuable data on the species distribution and antifungal susceptibility of oropharyngeal Candida isolates from geographically diverse areas of China. C. albicans remains the most common species but with increasing rates of azoles resistance.

[1]  U. Pennsylvania,et al.  Clinical and Laboratory Standards Institute , 2019, Springer Reference Medizin.

[2]  Y. Li,et al.  Five-Year National Surveillance of Invasive Candidiasis: Species Distribution and Azole Susceptibility from the China Hospital Invasive Fungal Surveillance Net (CHIF-NET) Study , 2018, Journal of Clinical Microbiology.

[3]  Jun Liu,et al.  Epidemiology and antifungal susceptibilities of yeast isolates causing invasive infections across urban Beijing, China. , 2017, Future microbiology.

[4]  R. Mouriño-Pérez,et al.  Candida species diversity and antifungal susceptibility patterns in oral samples of HIV/AIDS patients in Baja California, Mexico , 2016, Medical mycology.

[5]  A. Jayachandran,et al.  Oral Candidiasis among Cancer Patients Attending a Tertiary Care Hospital in Chennai, South India: An Evaluation of Clinicomycological Association and Antifungal Susceptibility Pattern , 2016, The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale.

[6]  P. Das,et al.  Species distribution & antifungal susceptibility pattern of oropharyngeal Candida isolates from human immunodeficiency virus infected individuals , 2016, The Indian journal of medical research.

[7]  H. Hua,et al.  Efficacy and safety of miconazole for oral candidiasis: a systematic review and meta-analysis. , 2016, Oral diseases.

[8]  B. Ataei,et al.  Candidiasis in Pediatrics; Identification and In vitro Antifungal Susceptibility of the Clinical Isolates , 2016, Iranian journal of pediatric hematology and oncology.

[9]  F. Kong,et al.  A Comprehensive Evaluation of the Bruker Biotyper MS and Vitek MS Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry Systems for Identification of Yeasts, Part of the National China Hospital Invasive Fungal Surveillance Net (CHIF-NET) Study, 2012 to 2013 , 2016, Journal of Clinical Microbiology.

[10]  A. Bitew,et al.  Spectrum and the In Vitro Antifungal Susceptibility Pattern of Yeast Isolates in Ethiopian HIV Patients with Oropharyngeal Candidiasis , 2016, International journal of microbiology.

[11]  M. Pinteala,et al.  Etiologic Agents and Antifungal Susceptibility of Oral Candidosis from Romanian patients with HIV-infection or type 1 diabetes mellitus , 2016, Polish journal of microbiology.

[12]  W. Hryniewicz,et al.  Usefulness of CHROMagar Candida Medium, Biochemical Methods – API ID32C and VITEK 2 Compact and Two MALDI-TOF MS Systems for Candida spp. Identification , 2016, Polish journal of microbiology.

[13]  G. Kerbauy,et al.  Oral Candida colonization in HIV-infected patients in Londrina-PR, Brazil: antifungal susceptibility and virulence factors. , 2015, Journal of infection in developing countries.

[14]  Xuelin Han,et al.  Occurrence of oral Candida colonization and its risk factors among patients with malignancies in China , 2015, Clinical Oral Investigations.

[15]  A. Berbéri,et al.  Epidemiology of Oropharyngeal Candidiasis in Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome Patients and CD4+ Counts , 2015, Journal of international oral health : JIOH.

[16]  L. Soares,et al.  Effect of the crude extract of Eugenia uniflora in morphogenesis and secretion of hydrolytic enzymes in Candida albicans from the oral cavity of kidney transplant recipients , 2015, BMC Complementary and Alternative Medicine.

[17]  J. Bagan,et al.  Current treatment of oral candidiasis: A literature review , 2014, Journal of clinical and experimental dentistry.

[18]  P. Hsueh,et al.  Comparison of the Accuracy of Two Conventional Phenotypic Methods and Two MALDI-TOF MS Systems with That of DNA Sequencing Analysis for Correctly Identifying Clinically Encountered Yeasts , 2014, PloS one.

[19]  A. Amani,et al.  Species distribution and antifungal susceptibility of Candida spp. isolated from superficial candidiasis in outpatients in Iran. , 2014, Journal de mycologie medicale.

[20]  Jianping Xu,et al.  Prevalent Drug Resistance Among Oral Yeasts from Asymptomatic Patients in Hainan, China , 2014, Mycopathologia.

[21]  E. Presterl,et al.  In Vitro Susceptibility of Candida Isolates from Organ Transplant Recipients to Newer Antifungals , 2014, Mycopathologia.

[22]  Ryoichi Sakamoto,et al.  Frequency of clinically isolated strains of oral Candida species at Kagoshima University Hospital, Japan, and their susceptibility to antifungal drugs in 2006–2007 and 2012–2013 , 2014, BMC oral health.

[23]  F. Kong,et al.  Yeast Identification Algorithm Based on Use of the Vitek MS System Selectively Supplemented with Ribosomal DNA Sequencing: Proposal of a Reference Assay for Invasive Fungal Surveillance Programs in China , 2013, Journal of Clinical Microbiology.

[24]  K. Rossem,et al.  A Prospective Two‐Year Assessment of Miconazole Resistance in Candida Spp. with Repeated Treatment with 0.25% Miconazole Nitrate Ointment in Neonates and Infants with Moderate to Severe Diaper Dermatitis Complicated by Cutaneous Candidiasis , 2013, Pediatric dermatology.

[25]  Yong-Gang Yao,et al.  Asymptomatic oral yeast carriage and antifungal susceptibility profile of HIV-infected patients in Kunming, Yunnan Province of China , 2013, BMC Infectious Diseases.

[26]  T. Calandra,et al.  ESCMID* guideline for the diagnosis and management of Candida diseases 2012: patients with HIV infection or AIDS. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[27]  M. Pfaller,et al.  Progress in Antifungal Susceptibility Testing of Candida spp. by Use of Clinical and Laboratory Standards Institute Broth Microdilution Methods, 2010 to 2012 , 2012, Journal of Clinical Microbiology.

[28]  G. Quindós,et al.  In Vitro Activities of New Triazole Antifungal Agents, Posaconazole and Voriconazole, Against Oral Candida Isolates from Patients Suffering from Denture Stomatitis , 2011, Mycopathologia.

[29]  C. Koga‐Ito,et al.  In vitro antifungal susceptibility of Candida spp. oral isolates from HIV-positive patients and control individuals. , 2011, Brazilian oral research.

[30]  A. Rodloff,et al.  Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-Year Analysis of Susceptibilities of Candida Species to Fluconazole and Voriconazole as Determined by CLSI Standardized Disk Diffusion , 2010, Journal of Clinical Microbiology.

[31]  M. Moshi,et al.  Species distribution and in vitro antifungal susceptibility of oral yeast isolates from Tanzanian HIV-infected patients with primary and recurrent oropharyngeal candidiasis , 2008, BMC Microbiology.

[32]  W. Coulter,et al.  In vitro susceptibility of oral Candida to seven antifungal agents. , 2005, Oral microbiology and immunology.

[33]  P. Wayne Reference method for broth dilution antifungal susceptibility testing of yeasts, Approved standard-second edition , 2002 .

[34]  P. Connolly,et al.  Does Long-Term Itraconazole Prophylaxis Result in In Vitro Azole Resistance in Mucosal Candida albicans Isolates from Persons with Advanced Human Immunodeficiency Virus Infection? , 2000, Antimicrobial Agents and Chemotherapy.

[35]  B. Gazzard,et al.  Unresponsive HIV-related oro-oesophageal candidosis--an evaluation of two new in-vitro azole susceptibility tests. , 1997, The Journal of antimicrobial chemotherapy.